抗慢性淋巴细胞白血病新药venetoclax药理作用及临床评价

抗慢性淋巴细胞白血病新药venetoclax药理作用及临床评价

张亚安,任莉萍,钮娴,张晴晴,周新月,潘喆

东南大学成贤学院制药与化学工程学院南京210088,东南大学成贤学院制药与化学工程学院南京210088,东南大学成贤学院制药与化学工程学院南京210088,东南大学成贤学院制药与化学工程学院南京210088,东南大学成贤学院制药与化学工程学院,东南大学成贤学院制药与化学工程学院

收稿日期:2017-03-29 修回日期:2017-09-11 出版日期:2017-11-25
基金资助:
江苏省高等学校大学生实践创新训练计划项目（项目编号：201612689021X；项目名称：药物超分子包合作用及其应用研究）；东南大学成贤学院大学生实践创新训练计划项目（项目编号：yox1778；项目名称：生理药理学微信数字平台的设计与实现）

Pharmacology and Clinical Evaluation of Venetoclax for the Treatment of Chronic Lymphocytic Leukemia

ZHANG Ya-an,REN Li-ping,NIU Xian,ZHANG Qing-qing,ZHOU Xin-yue and PAN Zhe

Department of Pharmaceutical and Chemical Engineering of Southeast University Chengxian College,Department of Pharmaceutical and Chemical Engineering of Southeast University Chengxian College,Department of Pharmaceutical and Chemical Engineering of Southeast University Chengxian College,Department of Pharmaceutical and Chemical Engineering of Southeast University Chengxian College,Department of Pharmaceutical and Chemical Engineering, Southeast University Chengxian College,Department of Pharmaceutical and Chemical Engineering, Southeast University Chengxian College

Received:2017-03-29 Revised:2017-09-11 Online:2017-11-25

摘要/Abstract

摘要： venetoclax为首个选择性口服B淋巴细胞瘤-2（Bcl-2）蛋白抑制剂，研究证实其治疗复发/难治慢性淋巴细胞白血病（CLL）具有可控的安全性，总体及完全有效率高。2016年4月11日，美国食品药品管理局（FDA）批准venetoclax用于治疗携带17p缺失突变且曾接受过至少一种治疗的CLL。本综述主要介绍venetoclax药物作用机制、药物代谢动力学、疗效、安全性及临床研究进展。

张亚安,任莉萍,钮娴,张晴晴,周新月,潘喆. 抗慢性淋巴细胞白血病新药venetoclax药理作用及临床评价[J]. .

ZHANG Ya-an,REN Li-ping,NIU Xian,ZHANG Qing-qing,ZHOU Xin-yue and PAN Zhe. Pharmacology and Clinical Evaluation of Venetoclax for the Treatment of Chronic Lymphocytic Leukemia[J]. .

参考文献

[1]赵楠, 周颖, 赵侠,等. 治疗慢性淋巴细胞白血病新药obinutuzumab的药理作用及临床评价[J]. 中国新药杂志, 2014,23(11):1227-1229.
[2]STEPHAN S, BARBARA E , JOHANNES S, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2016, 17(6):768-778.
[3]FDA: Venetoclax [EB/OL]. [2016-08-04]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf
[4]KERRY R, JOHN B. Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver[J]. Cancer Cell, 2016, 29(1):3-4.
[5]BEMARD M, LISA S, ANTHONY P. Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia [J]. J Oncol Pharm Practice, 2016, 0(0):1-16.
[6]CANG S, IRAGAVARAPU C, SAVOOJI J, et al. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development[J]. J Hematol Oncol, 2015, 8:129-137.
[7]DEL PG, POSTORINO M, PUPO L, et al. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.[J]. Drugs Today (Barc), 2016 ,52(4):249-260.
[8]SOUERS AJ, LEVERSON JD, BOGHAERT ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. [J]. Nat Med, 2013 ,19(2):202-208.
[9]JONES AK, FREISE KJ, AGARWAL SK, et al. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis [J]. AAPS J,2016,1-11.
[10]ROBERTS AW, DAVIDS MS, PAGEL JM, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia [J]. N Engl J Med, 2016, 374(4):311–22.
[11]SALEM AH, AGARWAL S, DUNBAR M, et al. Effect of low and high fat meals on the pharmacokinetics of venetoclax, a selective firstin-class bcl-2 inhibitor. [J]. J Clin Pharmacol, 2016. doi:10.1002/jcph.741
[12]DEEKS ED. Venetoclax: First Global Approval[J]. Drugs, 2016, 76(9):1-9.
[13]Ma S, BRANDER DM, SEYMOUR JF, et al. Deep and durable responses following venetoclax (ABT-199/GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a phase 1B study [J].Blood, 2015,126(23):830.
[14]SALLES GA, BOYD TE, MORSCHHAUSER F, et al. Updated safety andpreliminary efficacy data from a phase 1B study combining venetoclax (GDC-0199, ABT-199) with bendamustine/rituximab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia [J]. Blood., 2015,126(23): 829.
[15]FLINN IW, BRUNVAND M, CHOI MY, et al. Safety and efficacy of a combination of venetoclax (GDC-0199/ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia-results from a phase 1b study (GP28331) [J]. Blood, 2015,126(23): 494.
[16]NIH: Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) [EB/OL]. [2016-08-04]. https://clinicaltrials.gov/ct2/show/NCT02756897?term=Venetoclax rank=2

快速检索引用检索图表检索高级检索